Tharimmune (THAR) said Monday it plans to initiate a phase 2 study that will evaluate TH104 in reducing itch in patients with primary biliary cholangitis, a rare, chronic liver disease.

The clinical trial, expected to begin in 2025, follows results from a phase 1 study and recent regulatory feedback from the European Medicines Agency and the US Food and Drug Administration, the biotechnology company said.

Preliminary results from the trial, which has a planned enrollment of 40 patients, are expected in late 2025, the company said.